This company seems to have been delisted
Reason: Acquired by Crown Laboratories
Last recorded trade on: April 9, 2025
Source: https://www.businesswire.com/news/home/20250207314086/en/Crown-Laboratories-Completes-Acquisition-of-Revance-Therapeutics
Reason: Acquired by Crown Laboratories
Last recorded trade on: April 9, 2025
Source: https://www.businesswire.com/news/home/20250207314086/en/Crown-Laboratories-Completes-Acquisition-of-Revance-Therapeutics
Revance Therapeutics
RVNC
C$5.03
Share price
0.00%
Change (1 day)
-3.49%
Change (1 year)
Categories
Number of shares outstanding for Revance Therapeutics (RVNC)
Number of shares outstanding in September 2024 : 104,212,891
According to Revance Therapeutics's latest financial reports and stock price the company's current number of shares outstanding is 104,212,891. At the end of 2024 the company had 104,212,891 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Revance Therapeutics from 2013 to 2024
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2024 | 0.10 B | 20.32% |
| 2023 | 86.61 M | 8.1% |
| 2022 | 80.12 M | 17.77% |
| 2021 | 68.03 M | 7.48% |
| 2020 | 63.29 M | 38.73% |
| 2019 | 45.62 M | 25.57% |
| 2018 | 36.33 M | 15.05% |
| 2017 | 31.58 M | 11.98% |
| 2016 | 28.2 M | 6.58% |
| 2015 | 26.46 M | 12.64% |
| 2014 | 23.49 M | 32.39% |
| 2013 | 17.74 M |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | differencediff. | Country |
|---|---|---|---|
 MediciNova MNOV | 49,046,246 | -52.94% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 2,405,625,000 | 2,208.38% | 🇺🇸 USA |
 Biogen BIIB | 146,100,000 | 40.19% | 🇺🇸 USA |